Loading...
Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC
Gray, JE Villegas, A Daniel, D Vicente, D Murakami, S Hui, R Kurata, T Chiappori, A Lee, KH Cho, BC
Gray, JE
Villegas, A
Daniel, D
Vicente, D
Murakami, S
Hui, R
Kurata, T
Chiappori, A
Lee, KH
Cho, BC
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Article
Citation
Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Brief report: three-year overall survival with durvalumab after chemoradiotherapy in stage III NSCLC - Update from PACIFIC. J Thorac Oncol. 2019.